Investor FAQs
October 2, 2019
Due to the high volume of calls and emails from our shareholders, we wanted to address some
of the most common questions we have received.
Q: What was the date of the merger?
A: The merger was completed after the market closed on Friday, September 27, 2019.
Q: What was the stock price at the close of the merger?
A: Histogenics stock price at the time of closing was $0.1620. After the reverse split, this
translated to $9.72 as the Ocugen share price.
Q: What was the reverse split ratio?
A: Histogenics issued a 1 for 60 reverse split after the market closed on Friday, September 27,
2019. For example, if you owned 6,000 shares of Histogenics stock before the merger, you
would have 100 Ocugen shares after the merger.
Q: How many shares are outstanding?
A: As of the market opening on Monday, September 30, 2019, there were 10 million shares
outstanding. We’ve issued an additional 2.2 million shares to new investors as part of the
Pre-Merger Financing transaction, which results in 12.2 million shares outstanding.
Q: What is the float?
A: As of the market opening on Monday, September 30, 2019, the float is approximately 53%.
With the issuance of the additional shares, the float is approximately 61%.
Q: What is happening with fractional shares?
A: Broadridge Financial Solutions, Inc. will convert the fractional shares into cash and deposit
into the brokerage account. You can find contact information for them at
https://www.broadridge.com
Q: What caused the stock price to drop approximately 70% on the first day of trading?
A: We know of no negative news impacting the Ocugen stock. We believe the stock has been
unduly impacted by retail shareholders selling their position. Management believes in the
intrinsic value of Ocugen and is committed to developing our broad pipeline of innovative
therapies that address rare and underserved eye diseases. We look forward to sharing
more information about our pipeline at both the Cantor Global Healthcare Conference and
Chardan Genetic Medicines Conference, both of which are being webcast. You can sign up
to listen to the presentation through the events lin
Investing is for those who don't know how to trade
Recent OCGN News
- Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference • GlobeNewswire Inc. • 09/24/2024 11:30:00 AM
- Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop • GlobeNewswire Inc. • 09/09/2024 10:30:12 AM
- Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit • GlobeNewswire Inc. • 09/05/2024 11:00:07 AM
- Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:30:42 AM
- Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy • GlobeNewswire Inc. • 08/28/2024 10:30:32 AM
- Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 08/26/2024 11:02:41 AM
- Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading • PR Newswire (US) • 08/20/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/16/2024 08:16:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:00:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 05:03:56 PM
- Ocugen Provides Business Update with Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 10:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 10:06:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:18:41 AM
- Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa • GlobeNewswire Inc. • 08/05/2024 10:30:33 AM
- Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock • GlobeNewswire Inc. • 08/02/2024 07:22:33 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/01/2024 01:18:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 01:16:00 PM
- Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock • GlobeNewswire Inc. • 08/01/2024 01:15:46 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/31/2024 08:16:21 PM
- Ocugen, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 07/31/2024 08:15:04 PM
- Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/29/2024 11:02:15 AM
- Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy • GlobeNewswire Inc. • 07/25/2024 10:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:31:01 PM
- Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease • GlobeNewswire Inc. • 06/21/2024 11:00:00 AM
- Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 06/20/2024 10:30:31 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM